Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults must have a diagnosis of HS for at least 1 year prior to Baseline.~* HS lesions must be present in at least two distinct anatomical areas, one of which must be at least Hurley Stage II or Hurley Stage III.~* Subject must have stable HS for at least 60 days prior to Screening visit and at Baseline visit.~* Subject must have experienced an inadequate response to at least a 90-day treatment of oral antibiotics for treatment of HS.~* Subject must have a total AN count of greater than or equal to 3 at baseline.~Exclusion Criteria:~* Subject was previously treated with adalimumab or another anti-tumor necrosis factor (anti-TNF) therapy (e.g., infliximab or etanercept).~* Subject received any oral antibiotic treatment for HS within 28 days prior to Baseline.~* Subject received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to Baseline visit.~* If entering the study on concomitant oral analgesics for non-HS related pain:~  * Subject on opioid analgesics within 14 days prior to Baseline visit;~ * Subject not on a stable dose of non-opioid oral analgesics for at least 14 days prior to the Baseline visit (as needed is not considered a stable dose).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 12 weeks.
- Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
- Placebo/Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/Placebo (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
- Adalimumab Every Week (EW)/Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).